Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1) - PubMed (original) (raw)
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1)
A Tzanidis et al. J Mol Cell Cardiol. 2001 May.
Abstract
A. Tzanidis, S. Lim, R. D. Hannan, F. See, A. M. Ugoni and H. Krum. Combined Angiotensin and Endothelin Receptor Blockade Attenuates Adverse Cardiac Remodeling Post-Myocardial Infarction in the Rat: Possible Role of Transforming Growth Factor beta(1). Journal of Molecular and Cellular Cardiology (2001) 33, 969-981. Myocardial infarction (MI) is associated with activation of the vasoconstrictor peptides, angiotensin II (AngII) and endothelin-1 (ET-1), which are thought to contribute to adverse cardiac remodeling and dysfunction. The present study sought to determine whether combined AngII and ET receptor blockade improves cardiac remodeling over individual treatments in an experimental model of left ventricular myocardial infarction (LVMI) in the rat. Groups of eight female Sprague-Dawley rats were randomized at 24 h post-LVMI to 1 week treatment with either vehicle, an ET(A/B)receptor antagonist (bosentan), an AT(1)receptor antagonist (valsartan), or combined treatment. Vehicle-treated animals developed LV dysfunction with extensive accumulation of collagen type I and increased alpha(1)(I) procollagen mRNA compared to sham controls. Whilst individual receptor blockade with either bosentan or valsartan reduced LVEDP towards sham control levels, there were no significant changes to myocardial collagen deposition in comparison to vehicle. In contrast, improved ventricular function by combined treatment was associated with reduced type I collagen deposition within left ventricular non-infarct regions, as well as reduced peptide distribution and cardiac gene expression of the profibrogenic peptide, transforming growth factor beta(1)(TGF beta(1)). These data demonstrate that combined AngII and ET receptor blockade has beneficial effects on myocardial fibrogenesis over individual treatments during adverse cardiac remodeling early post-MI.
Copyright 2001 Academic Press.
Similar articles
- Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart.
Sun Y, Zhang JQ, Zhang J, Ramires FJ. Sun Y, et al. J Mol Cell Cardiol. 1998 Aug;30(8):1559-69. doi: 10.1006/jmcc.1998.0721. J Mol Cell Cardiol. 1998. PMID: 9737942 - Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Burchill LJ, et al. Clin Sci (Lond). 2012 Dec;123(11):649-58. doi: 10.1042/CS20120162. Clin Sci (Lond). 2012. PMID: 22715807 - Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Tao ZW, Huang YW, Xia Q, Xu QW. Tao ZW, et al. Chin Med J (Engl). 2005 Jan 20;118(2):146-54. Chin Med J (Engl). 2005. PMID: 15667801 - Endothelin antagonism in experimental ischemic heart failure: hemodynamic, structural and neurohumoral effects.
Mulder P, Richard V, Thuillez C. Mulder P, et al. Heart Fail Rev. 2001 Dec;6(4):295-300. doi: 10.1023/a:1011404224969. Heart Fail Rev. 2001. PMID: 11447304 Review. - Infarct scar: a dynamic tissue.
Sun Y, Weber KT. Sun Y, et al. Cardiovasc Res. 2000 May;46(2):250-6. doi: 10.1016/s0008-6363(00)00032-8. Cardiovasc Res. 2000. PMID: 10773228 Review.
Cited by
- Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.
Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Haryono A, et al. Biology (Basel). 2022 May 16;11(5):759. doi: 10.3390/biology11050759. Biology (Basel). 2022. PMID: 35625487 Free PMC article. Review. - Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease.
Paolisso P, Bergamaschi L, Saturi G, D'Angelo EC, Magnani I, Toniolo S, Stefanizzi A, Rinaldi A, Bartoli L, Angeli F, Donati F, Rucci P, Mattioli AV, Taglieri N, Pizzi C, Galiè N. Paolisso P, et al. Front Pharmacol. 2020 Jan 31;10:1606. doi: 10.3389/fphar.2019.01606. eCollection 2019. Front Pharmacol. 2020. PMID: 32082147 Free PMC article. - Pro-remodeling peptides modulate collagen α1(I) promoter activity in rat cardiac myofibroblasts.
Kisling A, Katwa LC. Kisling A, et al. Biochem Biophys Res Commun. 2019 Aug 6;515(4):693-698. doi: 10.1016/j.bbrc.2019.06.025. Epub 2019 Jun 8. Biochem Biophys Res Commun. 2019. PMID: 31186140 Free PMC article. - Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds.
Akershoek JJ, Brouwer KM, Vlig M, Boekema BKHL, Beelen RHJ, Middelkoop E, Ulrich MMW. Akershoek JJ, et al. PLoS One. 2017 Jun 14;12(6):e0179350. doi: 10.1371/journal.pone.0179350. eCollection 2017. PLoS One. 2017. PMID: 28614412 Free PMC article. - Modulation of angiotensin II signaling in the prevention of fibrosis.
Murphy AM, Wong AL, Bezuhly M. Murphy AM, et al. Fibrogenesis Tissue Repair. 2015 Apr 23;8:7. doi: 10.1186/s13069-015-0023-z. eCollection 2015. Fibrogenesis Tissue Repair. 2015. PMID: 25949522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical